Biocon Q3 profit dips 11% over Q2

Biocon Q3 FY15 revenues at Rs 779 Crore; PAT at Rs 91 crore

biocon-621x414-621x414

Biocon has announced its Q3 FY15 results. The third quarter revenues stood at Rs 779 Crore recording Rs 91 crore net profit. The company's profits have shown 11 percent dip compared to previous quarter and have shown 13 percent decrease year on year (Y-o-Y). Income has shown growth of 8 percent Y-o-Y and 1 percent sequentially.

The Biopharma segment recorded revenues of Rs. 436 Crore in Q3FY15, growing 4 percent YoY. And research service Research Services delivers 20 percent growth.

The Branded Formulations business recorded revenues of Rs. 105 Crore in Q3 FY15, registering a growth of 6 percent YoY. For 9M FY15, the vertical grew 11percent YoY, in line with the Indian Pharmaceutical Market (IPM).

The Research Services segment recorded Q3 sales of Rs. 220 Crore, delivering a growth of 20 percent YoY. Commenting on this performance, Mr Peter Bains, Director, Syngene International, said, "We are pleased with this quarter's robust performance which includes good traction from recent capacity expansions. Our order book is strong and we see this momentum continuing through Q4. We are on track to achieve our full year revenue growth guidance in the high teens."

Biocon, through its wholly owned subsidiary Biocon Research Limited (BRL), concluded the sale of its 10 percent stake in Syngene to M/s IVF Trustee Company Private Limited. Post this stake sale, the holding of Biocon (including stake held by Biocon Research Limited) in Syngene stands at 85.54percent.

Previous 1 Next

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

GST

GST: Boon or Bane for Healthcare?

Send this article by email

X